ClinicalTrials.gg
TerminatedNCT05536310TAVISUpdated Aug 21, 2026

TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease

An observational study in Aortic Valve Stenosis, Aortic Valve Regurgitation and Aortic Valve Stenosis With Insufficiency, sponsored by JenaValve Technology, Inc.. Terminated at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by JenaValve Technology, Inc. · Observational

How we know

Why this study was terminated
Inadequate study design which restricted study enrollment suitable for a registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
24
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.

Enrollment
97th of 98
24 · median 300
Started
2023
with 8 others
Observational
98 of 191
22 open now
Registered
152nd of 191
by date

Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 97th largest by enrollment of the 98 observational ones that give a count, is one of 9 that started in 2023, is one of 98 observational ones, and was the 152nd registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Aortic Valve Stenosis with a site in Germany, or all of them as a file.
02

Study summary

To collect information about the management of symptomatic severe Aortic Stenosis (AS) and Aortic Regurgitation (AR) using transcatheter aortic valve replacement (TAVI).

Read the detailed description

Aortic stenosis (AS) is a narrowing of the aortic valve opening causing restricted blood flow from the left ventricle to the aorta and may also affect the pressure in the left atrium. Aortic regurgitation (AR) is a condition where the aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of AS and AR may include fatigue and shortness of breath. Aortic valve disease can affect both elderly and younger populations. TAVIS Registry will collect data from patients suffering from either AS or AR using a minimally invasive transcatheter aortic valve implantation procedure.

03

Conditions studied

  • Aortic Valve Stenosis
  • Aortic Valve Regurgitation
  • Aortic Valve Stenosis With Insufficiency
  • Constriction, Pathologic
  • Aortic Valve Disease
  • Heart Valve Diseases
  • Cardiovascular Diseases in Old Age
  • Ventricular Outflow Obstruction
  • Aortic Stenosis, Severe

Keywords

  • Trilogy
  • Aortic Valve Disease
  • Transcatheter aortic valve replacement (TAVR)
  • Aortic Valve Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with symptomatic severe aortic regurgitation or symptomatic severe aortic stenosis undergoing treatment with JenaValve Trilogy Heart Valve System

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who have signed ICF and are indicated by their doctors to be treated with Trilogy Heart Valve System in line with the medical standard of care
  2. Patients with symptomatic severe aortic regurgitation (AR) or symptomatic, severe aortic stenosis (AS), who are at high risk for SAVR as documented by the heart team and Heart Team agrees that patient can undergo SAVR for "bail out"/to address unfavorable circumstances if necessary
  3. Patients 18 years of age or older
  4. Patient is willing to participate in the study, provides signed /Data Authorization Form and authorizes the sharing of data in the study
  5. The subject and treating physician agree the subject will return for all required post-procedure follow-up visits

Exclusion criteria

Exclusion Criteria:

  1. Patients who have known or to Nitinol (titanium and/or nickel), an anti-coagulation/anti- regimen or contrast medium that cannot be managed with premedication
  2. Patients who have active bacterial endocarditis or other active infections
  3. Pediatric (\<18 years) and/or pregnant/nursing patients
  4. Congenital/functional unicuspid, bicuspid or quadricuspid native aortic valve morphology
  5. Previous prosthetic aortic valve (bioprosthesis or mechanical) implant
  6. Echocardiographic evidence of current left heart thrombus
  7. Hypertrophic cardiomyopathy with or without obstruction.
  8. Access vessel characteristics that would preclude safe placement of the JenaValve 20Fr introducer sheath, such as severe obstructive calcification, severe tortuosity, or vessel diameter \<7mm.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
24 participants (actual)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Trilogy TAVI

    Patients receiving JenaValve Trilogy Heart Valve System for management of symptomatic, severe aortic stenosis (AS)/ aortic regurgitation (AR) who are at high risk for surgical aortic valve replacement (SAVR)

    Device: Transcatheter Aortic Valve Implantation (TAVI)

Interventions

  • DeviceTranscatheter Aortic Valve Implantation (TAVI)

    TAVI with the JenaValve Trilogy Heart Valve System

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    Mortality from any cause in patients receiving TAVI for AR or AS

    Time frame: 30-days post-index procedure

Secondary outcomes

  1. Death

    Reported death in patients participating in TAVIS Registry

    Time frame: 1 year

  2. Stroke

    Reported stroke in patients participating in TAVIS Registry

    Time frame: 30 days and 1 year

  3. Major vascular complications

    Reported vascular complications in patients participating in TAVIS Registry

    Time frame: 30 days

  4. Major and life-threatening bleeding

    Reported major and life-threatening bleeding complications in patients participating in TAVIS Registry

    Time frame: 30 days

  5. New conduction defects requiring permanent pacemaker

    Reported conduction defects requiring permanent pacemaker in patients participating in TAVIS Registry

    Time frame: 30 days

  6. Acute kidney injury stage 2-3

    Reported kidney injury complications in patients participating in TAVIS Registry

    Time frame: 7 days

  7. New onset atrial fibrillation

    Reported new onset atrial fibrillation in patients participating in TAVIS Registry

    Time frame: 30 days

07

Study locations

3 sites
  • Herz-und Diabeteszentrum NRW Ruhr-Universität Bochum Bad Oeynhausen
    Bad Oeynhausen, 32545, Germany
  • University Hospital of Cologne Heart Center
    Cologne, 50937, Germany
  • University Hospital Mainz
    Mainz, 55131, Germany
08

References and documents

Publications

  • Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Shernan S, Thavendiranathan P, Thomas JD, Weissman NJ. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017 Apr;30(4):303-371. doi: 10.1016/j.echo.2017.01.007. Epub 2017 Mar 14. No abstract available. PubMed 28314623 ↗
  • Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Jun 20;135(25):e1159-e1195. doi: 10.1161/CIR.0000000000000503. Epub 2017 Mar 15. No abstract available. PubMed 28298458 ↗
  • Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003 Jul;24(13):1231-43. doi: 10.1016/s0195-668x(03)00201-x. PubMed 12831818 ↗
  • Hamid N, Ranard LS, Khalique OK, Hahn RT, Nazif TM, George I, Ng V, Leon MB, Kodali SK, Vahl TP. Commissural Alignment After Transfemoral Transcatheter Aortic Valve Replacement With the JenaValve Trilogy System. JACC Cardiovasc Interv. 2021 Sep 27;14(18):2079-2081. doi: 10.1016/j.jcin.2021.07.025. No abstract available. PubMed 34556282 ↗
  • Treede H, Rastan A, Ferrari M, Ensminger S, Figulla HR, Mohr FW. JenaValve. EuroIntervention. 2012 Sep;8 Suppl Q:Q88-93. doi: 10.4244/EIJV8SQA16. PubMed 22995119 ↗
  • Poschner T, Werner P, Kocher A, Laufer G, Musumeci F, Andreas M, Russo M. The JenaValve pericardial transcatheter aortic valve replacement system to treat aortic valve disease. Future Cardiol. 2022 Feb;18(2):101-113. doi: 10.2217/fca-2021-0065. Epub 2021 Oct 14. PubMed 34647465 ↗
  • Ng VG, Khalique OK, Nazif T, Patel A, Hamid N, George I, Bapat V, Hahn R, Kodali S, Vahl TP. Treatment of Acute Aortic Insufficiency With a Dedicated Device. JACC Case Rep. 2021 Mar 24;3(4):645-649. doi: 10.1016/j.jaccas.2021.01.021. eCollection 2021 Apr. PubMed 34317595 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Jul 2024, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2022
First posted
Sep 10, 2022
StartActual
Aug 1, 2023
Primary completionActual
Jul 9, 2024
CompletionActual
Jul 9, 2024
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05536310
Lead sponsor
JenaValve Technology, Inc.
Responsible party
Sponsor
First posted
Sep 10, 2022
Start date
Aug 1, 2023
Primary completion
Jul 9, 2024
Completion
Jul 9, 2024
Last update
Aug 21, 2026

Study contacts

Stephan Baldus, MD
principal investigator · University Hospital of Cologne Heart Center
Hendrik Treede, MD
principal investigator · Johannes Gutenberg University Mainz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion